WallStSmart

Veritone Inc (VERI)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 181% more annual revenue ($258.90M vs $92.19M). ZEPP leads profitability with a -15.5% profit margin vs -121.2%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

VERI

Avoid

32

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 3.5
Piotroski: 4/9Altman Z: -4.07

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

VERIUndervalued (+86.1%)

Margin of Safety

+86.1%

Fair Value

$22.44

Current Price

$2.05

$20.39 discount

UndervaluedFair: $22.44Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

VERI1 strengths · Avg: 10.0/10
EPS GrowthGrowth
207.9%10/10

Earnings expanding 207.9% YoY

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

VERI4 concerns · Avg: 2.8/10
Price/BookValuation
8.9x4/10

Trading at 8.9x book value

Market CapQuality
$201.69M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-273.9%2/10

ROE of -273.9% — below average capital efficiency

Revenue GrowthGrowth
-26.0%2/10

Revenue declined 26.0%

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : VERI

The strongest argument for VERI centers on EPS Growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : VERI

The primary concerns for VERI are Price/Book, Market Cap, Return on Equity. Debt-to-equity of 7.26 is elevated, increasing financial risk.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

VERI profiles as a turnaround stock while ZEPP is a hypergrowth play — different risk/reward profiles.

VERI carries more volatility with a beta of 2.37 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - INFRASTRUCTURE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 32/100) and 43.0% revenue growth. VERI offers better value entry with a 86.1% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Veritone Inc

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Veritone, Inc. provides artificial intelligence (AI) computing solutions in the United States and the United Kingdom. The company is headquartered in Denver, Colorado.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?